By Adria Calatayud


Bayer's Nubeqa prostate cancer drug met its main goal in a late-stage trial, which the company said paves the way for regulatory submissions to extend the drug's uses.

The German pharmaceutical company said Wednesday that a Phase 3 clinical study that evaluated Nubeqa in combination with androgen deprivation therapy met its primary objective by increasing radiological progression-free survival in prostate cancer patients with metastasis.

The safety data of the trial confirmed the tolerability profile of the drug in advanced prostate cancer, the company said.

Bayer said it plans to prepare for regulatory submission with health authorities globally to expand the indication of the drug, which is already approved under the brand name Nubeqa for the treatment of patients with prostate cancer who are at high risk of developing metastatic disease and for those with metastatic hormone-sensitive prostate cancer.


Write to Adria Calatayud at adria.calatayud@wsj.com


(END) Dow Jones Newswires

07-17-24 0203ET